Data Manipulation Not Common, But Happens "More Than I Would Have Expected," US FDA's Sharpless Says

As fallout from the Novartis Zolgensma data manipulation incident continues, US FDA acting commissioner Norman Sharpless notes that "at some level we have to trust the sponsors."